WEBULL
WebtradeDownload

Trial Data Review Could Be A Key Test For ImmunityBio Stock (IBRX)

Simply Wall St · 1d ago
  • ImmunityBio reported that the QUILT-2.005 registrational trial in BCG-naïve NMIBC has reached database lock for Cohort A. This enables final efficacy analysis on 366 randomized patients treated with ANKTIVA plus BCG or BCG alone.
  • The move to final analysis builds on an FDA-requested interim readout that showed statistically significant longer complete response duration with ANKTIVA plus BCG. This directly tests whether ImmunityBio can extend its bladder cancer franchise earlier in the treatment pathway.
  • We will now look at how ImmunityBio's broader investment narrative is influenced by this QUILT-2.005 database lock milestone and analysis.
Seize the momentum around ImmunityBio's ANKTIVA readout and compare it with other targeted healthcare opportunities featured in our hand picked 34 healthcare AI stocks.

ImmunityBio Investment Narrative Recap

To own ImmunityBio, you need to believe ANKTIVA can support a broader immunotherapy platform, not just a single bladder cancer product. The business today is highly concentrated, with commercial activity tied largely to ANKTIVA in BCG unresponsive NMIBC and meaningful losses of about US$992.4 million on revenue of US$165.8 million. That makes execution on new indications central to the story.

The QUILT-2.005 database lock matters because it moves a registrational trial in BCG naive NMIBC into final analysis, which is a clear near term operational catalyst. The biggest risk still sits around clinical and regulatory outcomes for ANKTIVA beyond bladder cancer and the funding demands of a company with negative equity and higher risk liabilities as it pursues a multi program pipeline.

The completion of database lock in QUILT-2.005 ties directly into ImmunityBio’s broader push to extend ANKTIVA from BCG unresponsive into earlier bladder cancer settings. That aligns with the commercial ambition to serve a wider NMIBC patient pool and, if supported by data and regulators, could change how dependent the firm is on a single treatment line.

Recent commentary from founder Patrick Soon Shiong around upcoming sepsis trials using ANKTIVA underlines that management is already looking beyond oncology. Operationally, this widens the list of possible catalysts but also adds trial complexity and cost. For you as a shareholder, the key question is whether the business can turn this expanding clinical footprint into diversified, reimbursed indications before funding constraints and competition in immunotherapy narrow its options.

ImmunityBio's narrative projects US$1.5b revenue and US$688.6 million earnings by 2029. That profile assumes revenue rising at 106.7% per year and an earnings swing of roughly US$1.7b from an earnings loss of US$992.4 million today.

Uncover why ImmunityBio's fair value indicates a 72% potential upside to its current price, which could narrow quickly if ImmunityBio executes on its pipeline plans.

NasdaqGS:IBRX 1-Year Stock Price Chart
NasdaqGS:IBRX 1-Year Stock Price Chart

Exploring Other Perspectives

One alternate angle places more emphasis on the risk that ImmunityBio never fully reduces its dependence on ANKTIVA, even with this QUILT 2.005 database lock in progress. The most cautious analysts were still pencilling in about US$1.7b in revenue and US$719.9 million in earnings by 2029, and viewed that as a ceiling rather than a stretch. Those views were formed before this trial milestone. If you care about both upside and downside, it may be useful to compare several narratives and decide which assumptions align most closely with your own.

Explore 4 other ImmunityBio fair value estimates, including one that suggests it could be worth just $12.00!

The Verdict Is Yours

Don't just follow the ticker. Dig into the data and build a conviction that's truly your own.

Looking For More Investment Ideas Beyond ImmunityBio?

Once you have formed a view on ImmunityBio, it can help to set it beside a wider watchlist so you see how its risks and potential rewards compare with other opportunities across the market.